{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:33:14Z","timestamp":1772137994201,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2607,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1093\/annonc\/mds202","type":"journal-article","created":{"date-parts":[[2012,7,6]],"date-time":"2012-07-06T01:25:35Z","timestamp":1341537935000},"page":"2687-2695","source":"Crossref","is-referenced-by-count":21,"title":["A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma"],"prefix":"10.1016","volume":"23","author":[{"given":"F.","family":"Morschhauser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Recher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Milpied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gressin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Salles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Brice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Vey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Haioun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Colombat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.F.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Deconinck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Lazreg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bergougnoux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Delsol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Attal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mds202_bb0010","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"issue":"8","key":"10.1093\/annonc\/mds202_bb0015","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds202_bb0020","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds202_bb0025","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds202_bb0030","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds202_bb0035","doi-asserted-by":"crossref","first-page":"792A","DOI":"10.1182\/blood.V110.11.792.792","article-title":"Final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up","volume":"110","author":"Salles","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds202_bb0040","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood.V100.4.1141.h81602001141_1141_1152","article-title":"Intensive therapies in follicular non-Hodgkin lymphomas","volume":"100","author":"Hunault-Berger","year":"2002","journal-title":"Blood"},{"issue":"26","key":"10.1093\/annonc\/mds202_bb0045","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1200\/JCO.2005.07.019","article-title":"Treatment strategies in follicular lymphomas: current status and future perspectives","volume":"23","author":"Hiddemann","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds202_bb0050","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.med.59.060906.220345","article-title":"A decade of rituximab: improving survival outcomes in non-Hodgkin lymphoma","volume":"59","author":"Molina","year":"2008","journal-title":"Ann Rev Med"},{"issue":"8","key":"10.1093\/annonc\/mds202_bb0055","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mds202_bb0060","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"issue":"9759","key":"10.1093\/annonc\/mds202_bb0065","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mds202_bb0070","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1093\/annonc\/mds202_bb0075","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1093\/annonc\/mds202_bb0080","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2008.261","volume":"23","author":"Buske","year":"2009","journal-title":"Leukemia"},{"issue":"21","key":"10.1093\/annonc\/mds202_bb0085","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1093\/annonc\/mds202_bb0090","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mds202_bb0095","doi-asserted-by":"crossref","first-page":"v181","DOI":"10.1093\/annonc\/mdq184","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Dreyling","year":"2010","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1093\/annonc\/mds202_bb0100","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/sj.bmt.1704654","article-title":"Stem cell transplantation in follicular lymphoma: progress at last?","volume":"34","author":"Tse","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mds202_bb0105","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"issue":"3","key":"10.1093\/annonc\/mds202_bb0110","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2000.18.3.527","article-title":"High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up","volume":"18","author":"Apostolidis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds202_bb0115","first-page":"4","article-title":"Quantitative PCR detection of t(14;18) bcl-2\/JH fusion sequences in follicular lymphoma patients. Comparison of peripheral blood and bone marrow aspirate samples","volume":"6","author":"Bowman","year":"2004","journal-title":"JMD"},{"issue":"4","key":"10.1093\/annonc\/mds202_bb0120","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.bmt.1702147","article-title":"Quantitative detection of t(14;18)-positive cells in patients with follicular lymphoma before and after autologous bone marrow transplantation","volume":"25","author":"Hirt","year":"2000","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1093\/annonc\/mds202_bb0125","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1044-579X(03)00017-8","article-title":"Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab","volume":"13","author":"Hirt","year":"2003","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"10.1093\/annonc\/mds202_bb0130","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.2144\/98256cr05","article-title":"Quantitative detection of t(14;18)-positive cells by real-time quantitative PCR using fluorogenic probes","volume":"25","author":"Dolken","year":"1998","journal-title":"Biotechniques"},{"key":"10.1093\/annonc\/mds202_bb0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1093\/annonc\/mds202_bb0140","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds202_bb0145","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.V69.2.597.597","article-title":"Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow","volume":"69","author":"Anderson","year":"1987","journal-title":"Blood"},{"issue":"8","key":"10.1093\/annonc\/mds202_bb0150","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1093\/annonc\/mds202_bb0155","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1046\/j.1365-2141.1996.7062323.x","article-title":"Oligonucleotide clonospecific probes directed against the junctional sequence of t(14;18): a new tool for the assessment of minimal residual disease in follicular lymphomas","volume":"94","author":"Galoin","year":"1996","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1093\/annonc\/mds202_bb0160","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/mp.51.6.333","article-title":"Detection of t(14;18) carrying cells in bone marrow and peripheral blood from patients affected by non-lymphoid diseases","volume":"51","author":"Rauzy","year":"1998","journal-title":"Mol Pathol"},{"issue":"10","key":"10.1093\/annonc\/mds202_bb0165","first-page":"847","article-title":"Detection of residual disease in follicular lymphomas using the PCR technique: importance of clono-specific probes","volume":"85","author":"Al Saati","year":"1998","journal-title":"Bull Cancer"},{"key":"10.1093\/annonc\/mds202_bb0170","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds202_bb0175","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"5","key":"10.1093\/annonc\/mds202_bb0180","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/annonc\/mdg201","article-title":"Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as \u2018in vivo purge\u2019 and consolidative immunotherapy following autologous stem cell transplantation","volume":"14","author":"Mangel","year":"2003","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1093\/annonc\/mds202_bb0185","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdh425","article-title":"Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study","volume":"15","author":"Brugger","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mds202_bb0190","doi-asserted-by":"crossref","first-page":"262a","DOI":"10.1182\/blood.V104.11.914.914","article-title":"High-dose therapy\/ASCT with rituximab for in-vivo purging and post-ASCT consolidation in relapsed follicular lymphoma achieves prolonged clinical and molecular remissions","volume":"104","author":"Woods","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mds202_bb0195","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00277-006-0113-5","article-title":"Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B cell non-Hodgkin's lymphoma","volume":"85","author":"Neumann","year":"2006","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1093\/annonc\/mds202_bb0200","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1053\/beha.2002.0216","article-title":"Molecular remission and non-Hodgkin's lymphoma","volume":"15","author":"Darby","year":"2002","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"10.1093\/annonc\/mds202_bb0205","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2141.2008.07101.x","article-title":"Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients","volume":"141","author":"Hirt","year":"2008","journal-title":"Br J Haematol"},{"issue":"39","key":"10.1093\/annonc\/mds202_bb0210","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/jncimonographs\/lgn005","article-title":"Age-dependent prevalence and frequency of circulating t(14;18)-positive cells in the peripheral blood of healthy individuals","author":"D\u00f6lken","year":"2008","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"3","key":"10.1093\/annonc\/mds202_bb0215","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/gcc.10178","article-title":"Lymphoma- and leukemia-associated chromosomal translocations in healthy individuals","volume":"36","author":"Janz","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1093\/annonc\/mds202_bb0220","doi-asserted-by":"crossref","unstructured":"MDreylingRForstpointnerWLudwigThe addition of rituximab to fludarabine combination (R-FCM) significantly improves remission rates and overall survival in recurrent follicular as well as mantle cell lymphoma - follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]. Ann Oncol. 2005;16: 110. Abstract #252","DOI":"10.1200\/jco.2005.23.16_suppl.6528"},{"issue":"17","key":"10.1093\/annonc\/mds202_bb0225","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study","volume":"28","author":"Van Oers","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mds202_bb0230","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.8005","article-title":"Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy. 2010 ASCO Annual Meeting","volume":"28","author":"Pettengell","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mds202_bb0235","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1093\/annonc\/mds202_bb0240","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"issue":"16","key":"10.1093\/annonc\/mds202_bb0245","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1200\/JCO.2007.13.7729","article-title":"Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study","volume":"26","author":"Cartron","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mds202_bb0250","first-page":"1048","article-title":"Recombinant human interleukin-2 restores in vitro T-cell colony formation by peripheral blood mononuclear cells after autologous bone marrow transplantation","volume":"15","author":"Bosly","year":"1987","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1093\/annonc\/mds202_bb0255","first-page":"469","article-title":"Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation","volume":"12","author":"Roberts","year":"1993","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1093\/annonc\/mds202_bb0260","first-page":"377","article-title":"Reconstitution of lymphocyte subsets after peripheral blood stem cell transplantation: two-color flow cytometric analysis","volume":"13","author":"Ashihara","year":"1994","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1093\/annonc\/mds202_bb0265","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bmt.1700626","article-title":"Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow","volume":"19","author":"Talmadge","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mds202_bb0270","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1182\/blood.V92.5.1471","article-title":"Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation","volume":"92","author":"Guillaume","year":"1998","journal-title":"Blood"},{"issue":"9","key":"10.1093\/annonc\/mds202_bb0275","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.bmt.1700774","article-title":"Interleukin-12 induced cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants","volume":"19","author":"Lindgren","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"10.1093\/annonc\/mds202_bb0280","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"issue":"16","key":"10.1093\/annonc\/mds202_bb0285","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","article-title":"Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a \u2018vaccinal effect\u2019 of rituximab","volume":"113","author":"Hilchey","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1093\/annonc\/mds202_bb0290","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2009-10-248609","article-title":"Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response","volume":"116","author":"Ab\u00e8s","year":"2010","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419379761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419379761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/10\/2687\/13788510\/mds202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:26:20Z","timestamp":1624505180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419379761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0923753419379761"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mds202","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717952962.793458509","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717952962.793459745","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}